# EDGAR Filing Document

**Accession Number:** 0001889791
**File Stem:** 0001493152-26-007688
**Filing Date:** 2026-2
**Character Count:** 3154
**Document Hash:** 3097bf03e1d95fcb27a9269a67cac861
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001493152-26-007688.hdr.sgml**: 20260223

**ACCESSION NUMBER**: 0001493152-26-007688

**CONFORMED SUBMISSION TYPE**: RW

**PUBLIC DOCUMENT COUNT**: 1

**FILED AS OF DATE**: 20260223

**DATE AS OF CHANGE**: 20260223

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** INNOCAN PHARMA Corp
- **CENTRAL INDEX KEY:** 0001889791
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 000000000
- **STATE OF INCORPORATION:** Z4
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** RW

**SEC ACT:**
- **SEC FILE NUMBER:** 333-288899
- **FILM NUMBER:** 26662177

**BUSINESS ADDRESS:**
- **ADDRESS IS A NON US LOCATION:** YES
- **STREET 1:** 1015, 926 - 5 AVENUE SW
- **CITY:** CALGARY
- **PROVINCE COUNTRY:** Z4
- **ZIP:** T2P 0N7
- **BUSINESS PHONE:** 403-777-1519

**MAIL ADDRESS:**
- **ADDRESS IS A NON US LOCATION:** YES
- **STREET 1:** 1015, 926 - 5 AVENUE SW
- **CITY:** CALGARY
- **PROVINCE COUNTRY:** Z4
- **ZIP:** T2P 0N7

Innocan Pharma Corporation

1015, 926 – 5 Avenue SW

Calgary, Alberta T2P 0N7, Canada

February 23, 2026

**<u>VIA EDGAR</u>**

U.S. Securities and Exchange Commission

Division of Corporate Finance

100 F Street, N.E.

Washington, D.C. 20549

---

| | |
|:---|:---|
| **Re:** | **Innocan Pharma Corporation** |
|  | **Request for Withdrawal of Registration Statement on Form F-1** |
|  | **<u>File No. 333-288899</u>** |

---

Ladies and Gentlemen:

Pursuant to Rule 477 promulgated under the Securities Act of 1933, as amended (the "Securities Act"), Innocan Pharma Corporation, a corporation existing under the laws of Canada (the "Company"), hereby requests that the U.S. Securities and Exchange Commission (the "Commission") consent to the withdrawal, effective as of the date hereof, or at the earliest practicable date hereafter, of the Company's Registration Statement on Form F-1 (File No. 333-288899), originally filed on July 23, 2025, as thereafter amended (together with all exhibits thereto, the "Registration Statement"). The Company has determined not to proceed with its public offering and believes that withdrawal of the Registration Statement is consistent with the public interest and the protection of investors. The Company confirms that no securities were sold pursuant to the Registration Statement.

In accordance with Rule 457(p) of the Securities Act, and subject to compliance with the requirements thereof, the Company requests that all fees paid to the Commission in connection with the filing of the Registration Statement be credited for potential future use.

Accordingly, we hereby request that an order granting the withdrawal of the Registration Statement be issued by the Commission as soon as possible. Should you have any questions or require any further information please contact David Huberman, Esq. at 312.364.1633.

Very truly yours,

---

| | |
|:---|:---|
| **INNOCAN PHARMA CORPORATION** | **INNOCAN PHARMA CORPORATION** |
| By: | */s/ Iris Bincovich* |
|  | Iris Bincovich |
|  | Chief Executive Officer |

---

cc: David Huberman (Greenberg Traurig, LLP)